Aziyo Biologics, which makes regenerative medical products for various types of tissues, filed with the SEC on Monday to raise $ 58 million in an initial public offering.
Through its proprietary tissue processing platforms, the company has developed a portfolio of advanced regenerative medical products designed to be similar to natural biological material. Its core products are designed to meet the implantable / cardiovascular electronic device, orthopedic / spinal repair and soft tissue reconstruction markets.
The Silver Spring, Maryland-based company was founded in 2015 and reported sales of $ 42 million for the 12 months ended June 30, 2020. It plans to list on Nasdaq under the symbol AZYO. Aziyo Biologics filed a confidential filing on July 10, 2020. Piper Sandler, Cowen, Cantor Fitzgerald and Truist Securities are the associated bookkeepers in the transaction. No pricing conditions were disclosed.
The article Regenerative medicine company Aziyo Biologics files $ 58 million IPO originally appeared on the renaissancecapital.com website of IPO investment manager Renaissance Capital.
Disclosure of investments: The information and opinions expressed in this document have been prepared by Renaissance Capital research analysts and do not constitute an offer to buy or sell any securities. Renaissance capital Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of the companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.